Brief: Julphar Signs An Exclusive License And Production Agreement With Quantum Genomics

Quantum Genomics SA

06/12/2021 06:08

Dec 6 (Reuters) - GULF PHARMACEUTICAL INDUSTRIES
 JULPHAR.AD :
    * JULPHAR SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION
AGREEMENT WITH
QUANTUM GENOMICS
    * LICENSE AND PRODUCTION AGREEMETN FOR FIRIBASTAT
    * JULPHAR WILL BE MANUFACTURINGAND COMMERCIALIZATION PARTNER
FOR
FIRIBASTAT IN MENA, ALL AFRICAN COUNTRIES, CIS AND TURKEY
    * PRODUCT IS EXPECTED TO CONTRIBUTE SUBSTANTIALLY TO
JULPHAR'S
SALES AND PROFIT PERFORMANCE AFTER ITS MARKET LAUNCH IN 2024
    * MARKET LAUNCH IS EXPECTED IN 2024. PRODUCT DEVELOPMENT
MILESTONE
PAYMENTS AND EQUITY INVESTMENT ARE EXPECTED FOR 2022-2024
    * AGREED TO $5 MILLION UPFRONT AND DEVELOPMENT MILESTONE
PAYMENT
AND $2 MILLION EQUITY INVESTMENT
    * ALSO AGREED ROYALTIES AND SALES MILESTONE PAYMENTS DURING
COMMERCIALIZATION OF PRODUCT

Source text for Eikon:  ID:nADXE24445 
Further company coverage:  JULPHAR.AD 

 ((Reuters.Briefs@thomsonreuters.com;))